345 related articles for article (PubMed ID: 29336282)
1. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.
White AA; Doherty TA
Am J Rhinol Allergy; 2018 Jan; 32(1):7-11. PubMed ID: 29336282
[TBL] [Abstract][Full Text] [Related]
2. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
Eastman JJ; Cavagnero KJ; Deconde AS; Kim AS; Karta MR; Broide DH; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2017 Jul; 140(1):101-108.e3. PubMed ID: 28279492
[TBL] [Abstract][Full Text] [Related]
3. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
Buchheit KM; Cahill KN; Katz HR; Murphy KC; Feng C; Lee-Sarwar K; Lai J; Bhattacharyya N; Israel E; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
[TBL] [Abstract][Full Text] [Related]
4. Group 2 innate lymphoid cells and eosinophilic chronic rhinosinusitis.
Tojima I; Shimizu T
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):18-25. PubMed ID: 30507713
[TBL] [Abstract][Full Text] [Related]
5. Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD.
Badrani JH; Cavagnero K; Eastman JJ; Kim AS; Strohm A; Yan C; Deconde A; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2023 Nov; 152(5):1330-1335.e1. PubMed ID: 37543185
[TBL] [Abstract][Full Text] [Related]
6. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease.
Choi JH; Kim MA; Park HS
Curr Opin Allergy Clin Immunol; 2014 Feb; 14(1):1-6. PubMed ID: 24300420
[TBL] [Abstract][Full Text] [Related]
7. Lipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease.
Cavagnero KJ; Doherty TA
Ann Allergy Asthma Immunol; 2021 Feb; 126(2):135-142. PubMed ID: 32950684
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells.
Rusznak M; Peebles RS
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):38-45. PubMed ID: 30516547
[TBL] [Abstract][Full Text] [Related]
9. Cellular interactions in aspirin-exacerbated respiratory disease.
Badrani JH; Doherty TA
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):65-70. PubMed ID: 33306487
[TBL] [Abstract][Full Text] [Related]
10. Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.
Steinke JW; Liu L; Huyett P; Negri J; Payne SC; Borish L
J Allergy Clin Immunol; 2013 Oct; 132(4):856-65.e1-3. PubMed ID: 23806637
[TBL] [Abstract][Full Text] [Related]
11. Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease.
Luskin K; Thakrar H; White A
Immunol Allergy Clin North Am; 2020 May; 40(2):329-343. PubMed ID: 32278455
[TBL] [Abstract][Full Text] [Related]
12. Eosinophil production of prostaglandin D
Feng X; Ramsden MK; Negri J; Baker MG; Payne SC; Borish L; Steinke JW
J Allergy Clin Immunol; 2016 Oct; 138(4):1089-1097.e3. PubMed ID: 27423494
[TBL] [Abstract][Full Text] [Related]
13. Aspirin-exacerbated respiratory disease.
Wangberg H; White AA
Curr Opin Immunol; 2020 Oct; 66():9-13. PubMed ID: 32299015
[TBL] [Abstract][Full Text] [Related]
14. Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia.
Ho J; Bailey M; Zaunders J; Mrad N; Sacks R; Sewell W; Harvey RJ
Clin Exp Allergy; 2015 Feb; 45(2):394-403. PubMed ID: 25429730
[TBL] [Abstract][Full Text] [Related]
15. Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease.
Steinke JW; Negri J; Liu L; Payne SC; Borish L
J Immunol; 2014 Jul; 193(1):41-7. PubMed ID: 24890720
[TBL] [Abstract][Full Text] [Related]
16. Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
Liu T; Kanaoka Y; Barrett NA; Feng C; Garofalo D; Lai J; Buchheit K; Bhattacharya N; Laidlaw TM; Katz HR; Boyce JA
J Immunol; 2015 Oct; 195(8):3537-45. PubMed ID: 26342029
[TBL] [Abstract][Full Text] [Related]
17. Cysteinyl leukotriene E
Salimi M; Stöger L; Liu W; Go S; Pavord I; Klenerman P; Ogg G; Xue L
J Allergy Clin Immunol; 2017 Oct; 140(4):1090-1100.e11. PubMed ID: 28115217
[TBL] [Abstract][Full Text] [Related]
18. Evidence for the induction of Th2 inflammation by group 2 innate lymphoid cells in response to prostaglandin D
Tojima I; Matsumoto K; Kikuoka H; Hara S; Yamamoto S; Shimizu S; Kouzaki H; Shimizu T
Allergy; 2019 Dec; 74(12):2417-2426. PubMed ID: 31267527
[TBL] [Abstract][Full Text] [Related]
19. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Lewis E; Gakpo D; Hacker J; Sohail A; Taliaferro F; Berreondo Giron E; Asare C; Vukovic M; Bensko JC; Dwyer DF; Shalek AK; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2021 Aug; 148(2):574-584. PubMed ID: 34144111
[TBL] [Abstract][Full Text] [Related]
20. Group 2 innate lymphoid cells are increased in nasal polyps in patients with eosinophilic chronic rhinosinusitis.
Tojima I; Kouzaki H; Shimizu S; Ogawa T; Arikata M; Kita H; Shimizu T
Clin Immunol; 2016 Sep; 170():1-8. PubMed ID: 27422491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
